Targeting molecular pathophysiology of type II diabetes: preclinical development, animal proof of concept and safety profile evaluation of allosteric MAP Kinase modulators as insulin sensitizers (GLYKONTROL)

Datum objave: 16.06.2011

Kategorija: Aktualno na Univerzi

Allinky Biopharma

Contact Person

VEGA, MIguel (Mr.)
Allinky Biopharma

Contact
Telephone: +34-620-947503

Collaboration

Project Proposal


Title: Targeting molecular pathophysiology of type II diabetes: preclinical development, animal proof of concept and safety profile evaluation of allosteric MAP Kinase modulators as insulin sensitizers (GLYKONTROL)

Type Details: Targeting molecular pathophysiology of type II diabetes: preclinical development, animal proof of concept and safety profile evaluation of allosteric MAP Kinase modulators as insulin sensitizers (GLYKONTROL)


Programme (Collaboration EU R&D): FP7-HEALTH


Expiry Date: 2012-06-02


Target Partner

Expertise: Cell assays to evaluate insulin sensitizers
Animal proof of concept for insulin sensitizers and glycemic index modulators
Crystallography expertise to elucidate ligand-target binding
Formulation and medicinal chemistry to improve pharmacokinetic properties of chemical compounds
ADME evaluation in animals
Toxicology evaluation in animals


Organisation Details

Allinky Biopharma

Name: Allinky Biopharma

Region: COMUNIDAD DE MADRID

SPAIN


Type: SME (Small or Medium sized Enterprise)

Number of Employees: < 10



RCN: 87176

Quality Validation Date: 2011-06-02

Update Date: 2011-06-06